Clinical Trial Page

Clinical Trial Results:
A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.

Summary
EudraCT number	2004-001117-34
Trial protocol	ES IT
Global completion date	16 Jun 2010

Paediatric regulatory details
Is the trial part of an agreed EMA paediatric investigation plan?	No
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?	No
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?	No

Results information
Results version number	v1(current)
This version publication date	30 Jul 2016
First version publication date	30 Jul 2016
Other versions
Summary report(s)	2004-001117-34

Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03 for further information.

Clinical Trial Page

Clinical Trial Results:
A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Clinical Trial Page

Clinical Trial Results: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Clinical Trial Results:
A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.